Evaluation of an Antisense Oligonucleotide Targeting CAG Repeats: A Patient-Customized Therapy Study for Huntington’s Disease
Huntington’s disease is a genetic disorder characterized by progressive neuronal cell damage in some areas of the brain; symptoms are commonly associated with chorea, rigidity and dystonia. The symptoms in Huntington’s Disease are caused by a pathological increase in the number of Cytokine-Adenine-G...
Saved in:
| Main Authors: | Sergio Adrian Ocampo-Ortega, Vivany Maydel Sierra-Sanchez, Citlali Margarita Blancas-Napoles, Asdrúbal González-Carteño, Elvia Mera-Jiménez, Martha Edith Macías-Pérez, Adriana Hernandez-Guerra, Rodrigo Romero-Nava, Fengyang Huang, Enrique Hong, Santiago Villafaña |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2024-12-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/14/12/1607 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Gene Silencing Therapies for Huntington’s Disease
by: Chunlan Hao, et al.
Published: (2025-05-01) -
Antisense oligonucleotides for the arterial hypertension mechanisms study and therapy
by: L. O. Klimov, et al.
Published: (2018-04-01) -
Pharmacokinetics of antisense oligonucleotide drugs
by: M. R. Khaitov, et al.
Published: (2013-04-01) -
In vivo efficacy and safety of systemically administered serinol nucleic acid-modified antisense oligonucleotides in mouse kidney
by: Toshiki Tsuboi, et al.
Published: (2025-03-01) -
Altered huntingtin−chromatin interactions predict transcriptional and epigenetic changes in Huntington's disease
by: Jocelynn R. Pearl, et al.
Published: (2025-05-01)